Pionyr Immunotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 64

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $48M

Pionyr Immunotherapeutics General Information

Description

Developer of cancer immunotherapies designed to target the tumor microenvironment to improve the body's antitumor immunity. The company's immunotherapies improve the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity, enabling patients to combat cancer, particularly in combination with checkpoint inhibitors.

Contact Information

Formerly Known As
Precision Immune
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 2 Tower Place
  • Suite 800
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pionyr Immunotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 04-Aug-2023 $48M 00000 0000 Completed Clinical Trials - Phase 1
9. Secondary Transaction - Private 01-Apr-2023 00000 Completed Clinical Trials - Phase 1
8. Secondary Transaction - Private 00000 Completed Clinical Trials - General
7. Later Stage VC 01-Jul-2020 00000 00000 00000 Completed Clinical Trials - General
6. Early Stage VC (Series B) 28-Mar-2018 0000 000.00 Completed Clinical Trials - General
5. Early Stage VC (Series A1) 04-Jan-2017 000 00.00 000.00 Completed Clinical Trials - General
4. Early Stage VC (Series A) 08-May-2015 00.000 00.000 00.000 Completed Pre-Clinical Trials
3. Accelerator/Incubator Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Pionyr Immunotherapeutics’s complete valuation and funding history, request access »

Pionyr Immunotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 2,094,892 $0.000100 $0.06 $0.71 $0.71 1x $0.71 3.45%
To view Pionyr Immunotherapeutics’s complete cap table history, request access »

Pionyr Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer immunotherapies designed to target the tumor microenvironment to improve the body's antitumor immuni
Drug Discovery
South San Francisco, CA
64 As of 2023
00000
0000 0000-00-00
000000&0 00000

000000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000

000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
000000&0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pionyr Immunotherapeutics Competitors (90)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
Gadeta Formerly VC-backed Utrecht, Netherlands 00 00.000 000000&0 00.000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Priothera Venture Capital-Backed Dublin, Ireland 00 000.00 00000000000 000.00
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
You’re viewing 5 of 90 competitors. Get the full list »

Pionyr Immunotherapeutics Patents

Pionyr Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3239339-A1 Fibrosis treatment with anti-trem2 antibodies Pending 29-Nov-2021 00000000000
AU-2022396551-A1 Fibrosis treatment with anti-trem2 antibodies Pending 29-Nov-2021 00000000000
US-20220153832-A1 Anti-marco antibodies and uses thereof Active 18-Nov-2020 000000000
US-11572407-B2 Anti-marco antibodies and uses thereof Active 18-Nov-2020 000000000 00
AU-2021382658-A1 Anti-marco antibodies and uses thereof Pending 18-Nov-2020 C07K16/28
To view Pionyr Immunotherapeutics’s complete patent history, request access »

Pionyr Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pionyr Immunotherapeutics Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gilead Sciences Corporation Minority 000 0000 000000 0
John Freund Angel (individual) Minority 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
Mission BioCapital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Pionyr Immunotherapeutics FAQs

  • When was Pionyr Immunotherapeutics founded?

    Pionyr Immunotherapeutics was founded in 2015.

  • Who is the founder of Pionyr Immunotherapeutics?

    Matthew Krummel Ph.D and Sachdev Sidhu Ph.D are the founders of Pionyr Immunotherapeutics.

  • Where is Pionyr Immunotherapeutics headquartered?

    Pionyr Immunotherapeutics is headquartered in South San Francisco, CA.

  • What is the size of Pionyr Immunotherapeutics?

    Pionyr Immunotherapeutics has 64 total employees.

  • What industry is Pionyr Immunotherapeutics in?

    Pionyr Immunotherapeutics’s primary industry is Drug Discovery.

  • Is Pionyr Immunotherapeutics a private or public company?

    Pionyr Immunotherapeutics is a Private company.

  • What is the current valuation of Pionyr Immunotherapeutics?

    The current valuation of Pionyr Immunotherapeutics is 0000.

  • What is Pionyr Immunotherapeutics’s current revenue?

    The current revenue for Pionyr Immunotherapeutics is 000000.

  • How much funding has Pionyr Immunotherapeutics raised over time?

    Pionyr Immunotherapeutics has raised $353M.

  • Who are Pionyr Immunotherapeutics’s investors?

    Gilead Sciences, John Freund, Johnson & Johnson Innovation - JLABS, Mission Bay Capital, and Mission BioCapital are 5 of 17 investors who have invested in Pionyr Immunotherapeutics.

  • Who are Pionyr Immunotherapeutics’s competitors?

    Marengo Therapeutics, Gadeta, NexImmune, Priothera, and Iovance Biotherapeutics are some of the 90 competitors of Pionyr Immunotherapeutics.

  • When was Pionyr Immunotherapeutics acquired?

    Pionyr Immunotherapeutics was acquired on 04-Aug-2023.

  • Who acquired Pionyr Immunotherapeutics?

    Pionyr Immunotherapeutics was acquired by Ikena Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »